299 related articles for article (PubMed ID: 28512671)
21. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
[TBL] [Abstract][Full Text] [Related]
22. Refractory pityriasis rubra pilaris treated with etanercept, adalimumab, or ustekinumab: A retrospective investigation.
Maloney NJ; Hisaw LD; Worswick S
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 29034547
[TBL] [Abstract][Full Text] [Related]
23. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis.
Loft ND; Skov L; Iversen L; Gniadecki R; Dam TN; Brandslund I; Hoffmann HJ; Andersen MR; Dessau RB; Bergmann AC; Andersen NM; Andersen PS; Bank S; Vogel U; Andersen V
Pharmacogenomics J; 2018 May; 18(3):494-500. PubMed ID: 28696418
[TBL] [Abstract][Full Text] [Related]
24. Real-world outcome analysis of continuously and intermittently treated patients with moderate to severe psoriasis after switching to a biologic agent.
Hjalte F; Steen Carlsson K; Schmitt-Egenolf M
Dermatology; 2015; 230(4):347-53. PubMed ID: 25721571
[TBL] [Abstract][Full Text] [Related]
25. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
Al-Mutairi N; Nour T
Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
[TBL] [Abstract][Full Text] [Related]
26. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
Phan C; Beauchet A; Burztejn AC; Severino-Freire M; Barbarot S; Girard C; Lasek A; Reguiai Z; Hadj-Rabia S; Abasq C; Brenaut E; Droitcourt C; Perrussel M; Mallet S; Phan A; Lacour JP; Khemis A; Bourrat E; Chaby G; Deborde R; Plantin P; Maruani A; Piram M; Maccari F; Fougerousse AC; Kupfer-Bessaguet I; Balguérie X; Barthelemy H; Martin L; Quiles-Tsimaratos N; Mery-Brossard L; Pallure V; Lons-Danic D; Bouilly-Auvray D; Beylot-Barry M; Puzenat E; Aubin F; Mahé E; ;
J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1984-1992. PubMed ID: 30883928
[TBL] [Abstract][Full Text] [Related]
27. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
Ross C; Marshman G; Grillo M; Stanford T
Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
[TBL] [Abstract][Full Text] [Related]
28. Paradoxical case effects of psoriasis following adalimumab therapy: A case series.
Zangrilli A; Bavetta M; Mazzilli S; Garofalo V; Bianchi L
Dermatol Ther; 2018 Nov; 31(6):e12729. PubMed ID: 30239070
[No Abstract] [Full Text] [Related]
29. The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab.
Chiu HY; Chu TW; Cheng YP; Tsai TF
PLoS One; 2015; 10(11):e0142930. PubMed ID: 26566272
[TBL] [Abstract][Full Text] [Related]
30. Serial biologic therapies in psoriasis patients: A 12-year, single-center, retrospective observational study.
Cozzani E; Wei Y; Burlando M; Signori A; Parodi A
J Am Acad Dermatol; 2020 Jan; 82(1):37-44. PubMed ID: 31150706
[TBL] [Abstract][Full Text] [Related]
31. Adverse Reactions to Biologics in Psoriasis.
Lockwood SJ; Prens LM; Kimball AB
Curr Probl Dermatol; 2018; 53():1-14. PubMed ID: 29131033
[TBL] [Abstract][Full Text] [Related]
32. Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial.
Atalay S; van den Reek JMPA; van Vugt LJ; Otero ME; van de Kerkhof PCM; den Broeder AA; Kievit W; de Jong EMGJ
BMC Dermatol; 2017 May; 17(1):6. PubMed ID: 28482858
[TBL] [Abstract][Full Text] [Related]
33. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
[TBL] [Abstract][Full Text] [Related]
34. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Warren RB; Smith CH; Yiu ZZN; Ashcroft DM; Barker JNWN; Burden AD; Lunt M; McElhone K; Ormerod AD; Owen CM; Reynolds NJ; Griffiths CEM
J Invest Dermatol; 2015 Nov; 135(11):2632-2640. PubMed ID: 26053050
[TBL] [Abstract][Full Text] [Related]
35. Exacerbation of infliximab-induced paradoxical psoriasis after ustekinumab therapy.
Suh HY; Ahn JY; Park MY; Youn JI
J Dermatol; 2018 Mar; 45(3):332-333. PubMed ID: 28295521
[No Abstract] [Full Text] [Related]
36. Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a.
Leonardi CL
Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S74-7. PubMed ID: 27551698
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy of cyclosporine and anti-tumor necrosis factor α in psoriasis: a case series of 10 patients.
Cohen Barak E; Kerner M; Rozenman D; Ziv M
Dermatol Ther; 2015; 28(3):126-30. PubMed ID: 25640261
[TBL] [Abstract][Full Text] [Related]
38. A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis.
Hu Y; Chen Z; Gong Y; Shi Y
Clin Drug Investig; 2018 Mar; 38(3):191-199. PubMed ID: 29249053
[TBL] [Abstract][Full Text] [Related]
39. Patient Preference for Dosing Frequency Based on Prior Biologic Experience.
Zhang M; Carter C; Olson WH; Johnson MP; Brennem SK; Lee S; Farahi K
J Drugs Dermatol; 2017 Mar; 16(3):220-226. PubMed ID: 28301617
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and Safety of Systemic Therapy for Psoriasis in Older Adults: A Systematic Review.
van Winden MEC; van der Schoot LS; van de L'Isle Arias M; van Vugt LJ; van den Reek JMPA; van de Kerkhof PCM; de Jong EMGJ; Lubeek SFK
JAMA Dermatol; 2020 Nov; 156(11):1229-1239. PubMed ID: 32822455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
